• Username (E-mail)
  • Password
Dow 19,805 -0.1%  EStoxx50 3,294 0.3%  Nikkei 19,072 0.9%  EUR 1.0638 0.1% 
Nasdaq 5,556 0.3%  FTSE100 7,248 0.4%  Yen 114.6090 0.1%  Oil 54.4 0.3% 
S&P500 2,272 0.2%  DAX 11,599 0.5%  GBP 1.2279 0.1%  Gold 1,202 -1.5% 

Gilead Sciences share [Symbol: GILD / ISIN: US3755581036]

01/11/2017 07:02:37 AM
01/11/2017 07:02:37 AM UTC-0500

EC Grants Marketing Authorization For Gilead's Vemlidy


(RTTNews) - Gilead Sciences Inc. (GILD) announced that the European Commission has granted marketing authorization for Vemlidy (tenofovir alafenamide, TAF) 25 mg, a once-daily tablet for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg).

The marketing authorization allows for the marketing of TAF in the 28 countries of the European Union, Norway and Iceland.

TAF is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to Gilead's Viread (tenofovir disoproxil fumarate, TDF) 245 mg, but at one-tenth the dose. Data show that because TAF has greater plasma stability and more efficiently delivers tenofovir to hepatocytes (cells of the liver) compared to TDF, it can be given at a lower dose, which means there is less tenofovir in the bloodstream. By reducing exposure to tenofovir, TAF is associated with improved renal and bone laboratory safety parameters compared to TDF in clinical trials.

Vemlidy was approved by the U.S. Food and Drug Administration on November 10, 2016 for the treatment of chronic HBV infection in adults with compensated liver disease, and by the Japanese Ministry of Health, Labour and Welfare on December 19, 2016 for the suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function.

Analyst Opinions for Gilead Sciences Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
01/11/13
Gilead Sciences boerse.de-Aktienbrief
01/10/13
Gilead Sciences Aktienservice Research
12/18/12
Gilead Sciences UBS AG
12/14/12
Gilead Sciences Goldman Sachs Group Inc.
11/15/12
Gilead Sciences RBC Capital Markets

Add or Edit Instrument

Related Stocks

Gilead Sciences Inc. 72.13 0.31% Gilead Sciences Inc.

Stock Market

News Ticker

News

  • News on Stocks
  • All News
pagehit